MAPT and Alzheimer disease: To explore whether abnormalities of UFMylation are influenced by AD disease progression, we specifically examined the expression of UFM1 and UFSP2 and their correlation with tau in the earlier-affected superior temporal cortex and the later-affected frontal cortex.